SumTotal Systems Inc. (Nasdaq: SUMT) 41.8% HIGHER; In a 13D filing on SumTotal, Vista Equity Partners disclosed a $3.25 per share offer for the company.
Legacy Reserves LP (Nasdaq: LGCY) 29.6% HIGHER; received a proposal from Apollo Management VII, LP to acquire all of the outstanding units of Legacy Reserves LP at a cash purchase price of $14.00 per unit, subject to adjustment for any distributions paid to the partnership's limited partners. Click here for the full report.
Sun Micro (Nasdaq: JAVA) 21.7% LOWER; according to reports from the Wall Street Journal, merger talks between IBM (NYSE: IBM) and JAVA were close to unraveling after Sun's board rejected a formal acquisition offer by IBM. On Sunday, IBM withdrew its offer to buy Sun, according to a person familiar with the matter.
NII Holdings, Inc. (Nasdaq: NIHD) 21% LOWER; today announced its net subscriber results for the quarter ...
UBS upgrades Infineon (NYSE: IFX) from Neutral to Buy, citing the likelihood of government-backed ...
StreetInsider.com Morning Movers:
Chesapeake Energy Corp. (NYSE: CHK) 28% HIGHER; Updates Financial and Operational Plans Through 2010. Cutting capex, common shares to be offered.
General Motors (NYSE: GM) 22% HIGHER; US Considering $15B short-term loan package for automakers
Allos Therapeutics, Inc. (NASDAQ: ALTH) 21% LOWER; announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate (PDX) in patients with relapsed or refractory peripheral T-cell lymphoma. 29 of 109 evaluable patients (27%) achieved either a complete or partial response.
Human Genome ...
StreetInsider.com Morning Movers:
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) 76% HIGHER; announced positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone compared to docetaxel and prednisone alone for first-line treatment of metastatic castrate resistant prostate cancer. The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel was approved by the FDA based on a survival advantage of 2.4 months over mitoxantrone.
Infineon Technologies AG (NYSE: IFX) 28% LOWER; reports large Q4 loss and sees 2009 revenues down at least 15% from 2008.
Grey Wolf Inc. (NYSE: GW) 22% HIGHER; Precision Drilling Trust and Grey Wolf, Inc. Clarify ...
Citi reduces estimates on nine companies in Semiconductor industry - Altera (Nasdaq: ALTR), Advanced Micro (NYSE: AMD), Integrated Device Technology (Nasdaq: IDTI), Infineon Technologies (NYSE: IFX), NVIDIA (Nasdaq: NVDA), QUALCOMM (Nasdaq: QCOM), STMicro (NYSE: STM), Texas Instruments (NYSE: TXN), and Xilinx ...
